Nutritional Intervention and DNA Damage of Patients With HBOC

Plain-language summary

This study examines the effect of antioxidant therapy on DNA damage in women diagnosed with hereditary breast and ovarian cancer (HBOC). It enrolled volunteer female patients over the age of 18 who had been diagnosed with HBOC. This is a study without a phase and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

Not Applicable

Status

Completed

Sponsor

Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado

Intervention

Antioxidant therapy

Start date

11/28/2017

Estimated completion

12/31/2022

Countries

Mexico

Related genes

Locations

• Mexico City, Mexico

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Female patients diagnosed with HBOC according to the Mexican Consensus of Breast Cancer
* Patients over 18 years who voluntarily agree to participate in the study and sign the informed consent.

Exclusion Criteria:

* Patients with end-stage chronic kidney failure, heart failure, liver failure, rheumatoid arthritis, non-inherited AC or HIV.
* Patients who carry out a structured exercise plan (rehabilitation) at the time of inclusion in the study.
* Patients who carry out a structured eating plan (adherence to diet) or who are consuming a food supplement at the time of inclusion in the study.
* Patients with significant primary clinical disorders: hematological (hemoglobin \<13 in men and \<12 in women), renal (creatinine\> 3), neurological (other than epilepsy).